11,409
Views
15
CrossRef citations to date
0
Altmetric
EDITORIAL

Soft drugs: design principles, success stories, and future perspectives

ORCID Icon
Pages 645-650 | Received 08 Apr 2020, Accepted 28 May 2020, Published online: 20 Jun 2020

Figures & data

Figure 1. Illustration of the effects that metabolites have on the overall effect and toxicity of therapeutic agents. (a) Case of a hypothetical drug (D) that is metabolized into active, toxic, and inactive metabolites (Ma, Mt, and Mi, respectively). Corresponding time-profiles for concentrations, effects, and toxicities (arbitrary units) are shown for all components assuming that D is metabolized with different rates into these metabolites and they all have different elimination rates as well as activities and toxicities. For the case shown here, most of the effect is contributed by the original drug D and its active metabolite Ma, but most of the toxicity results from the toxic metabolite Mt. (b) Same for a hypothetical soft drug (SD) that is metabolized rapidly into a single inactive metabolite Mi of negligible activity and toxicity. Contrary to A, both activity and toxicity are driven only by those of the original SD even if Mi concentrations are quite high. Hence, complex PK profiles and toxicities due to reactive metabolites are avoided, and activity and toxicity can be better controlled. Time-profiles were obtained using single-compartment models with absorption, metabolism, and elimination rate constants (kabs, km,a, kel, etc.) and corresponding differential equations as indicated. All effects and toxicities were assumed to be directly proportional with concentrations (i.e. no effect compartment).

Figure 1. Illustration of the effects that metabolites have on the overall effect and toxicity of therapeutic agents. (a) Case of a hypothetical drug (D) that is metabolized into active, toxic, and inactive metabolites (Ma, Mt, and Mi, respectively). Corresponding time-profiles for concentrations, effects, and toxicities (arbitrary units) are shown for all components assuming that D is metabolized with different rates into these metabolites and they all have different elimination rates as well as activities and toxicities. For the case shown here, most of the effect is contributed by the original drug D and its active metabolite Ma, but most of the toxicity results from the toxic metabolite Mt. (b) Same for a hypothetical soft drug (SD) that is metabolized rapidly into a single inactive metabolite Mi of negligible activity and toxicity. Contrary to A, both activity and toxicity are driven only by those of the original SD even if Mi concentrations are quite high. Hence, complex PK profiles and toxicities due to reactive metabolites are avoided, and activity and toxicity can be better controlled. Time-profiles were obtained using single-compartment models with absorption, metabolism, and elimination rate constants (kabs, km,a, kel, etc.) and corresponding differential equations as indicated. All effects and toxicities were assumed to be directly proportional with concentrations (i.e. no effect compartment).

Table 1. Rationally designed or accidental soft drugs that are approved for clinical use (trademark provided) or have reached clinical development. For each compound, the entity responsible for its development, the year of the first publication, and the approved trademark (if available) are also included.

Figure 2. Clinically approved SDs including both rationally designed ones (top section, shown in parallel with the original drug structures that served as lead for their design in the right column) and accidental ones (bottom row). The metabolically labile soft spots are highlighted in magenta.

Figure 2. Clinically approved SDs including both rationally designed ones (top section, shown in parallel with the original drug structures that served as lead for their design in the right column) and accidental ones (bottom row). The metabolically labile soft spots are highlighted in magenta.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.